Co-infection of SENV-D among chronic hepatitis C patients treated with combination therapy with high-dose interferon-alfa and ribavirin

Table 2 Comparison of clinical and virological features between sustained viral responders (SVR) and non-responders (NR) of CHC patients after combination therapy

	HCV response		P
	NR (n = 51)	SVR (n = 105)
Sex (male) (%)	31 (60.8)	61 (58.1)	NS
Age (yr)	51.24 ± 11.3	46.4 ± 11.3	0.014
Serum ALT (IU/L)	122.2 ± 105.0	140.9 ± 189.9	NS
Normal ( ≤ 34 IU/L) (%)	4 (18.2)	18 (81.8)	NS
Abnormal (> 34 IU/L) (%)	47 (34.6)	87 (65.4)
HCV RNA levels (log IU/mL)	5.90 ± 0.62	5.73 ± 0.68	NS
High level (≥ 200 000 IU/mL) (%)	39 (39.4)	60 (60.6)	0.019
Low level (< 200 000 IU/mL) (%)	12 (21.1)	45 (78.9)
HCV genotype 1b (%)	44 (86.3)	32 (30.5)	<0.0001
Positive SENV-D DNA (%)	16 (31.4)	41 (39.0)	NS
Histology (HAI scores)
Patients no.	37	85
Peri-portal necrosis	1.08 ± 1.30	1.091 ± 1.323	NS
Intralobular necrosis	0.278 ± 0.61	0.64 ± 0.97	0.037
Portal inflammation	2.03 ± 1.17	1.89 ± 1.25	NS
Total score (grading)	3.32 ± 2.22	3.60 ± 2.59	NS
Fibrosis	1.41 ± 1.38	1.157 ± 1.31	NS

Results are expressed as mean±SD. HAI: histological activity index, NS: no significance.